The reliability of the IL-6, sIL-6R and sgp130 response to a preloaded time trial

被引:0
|
作者
I. Walshe
P. Robson-Ansley
A. St Clair Gibson
C. Lawrence
K. G. Thompson
L. Ansley
机构
[1] Northumbria University,Department of Sport and Exercise Sciences
[2] GlaxoSmithKline Nutritional Healthcare R&D,undefined
来源
关键词
Exercise; IL-6; sIL-6R; Time trial; Reliability;
D O I
暂无
中图分类号
学科分类号
摘要
Interleukin-6 (IL-6) is a cytokine that can mediate numerous biological actions including fatigue. Circulating IL-6 increases during prolonged exercise, and furthermore, the signalling receptors sIL-6R and sgp130 are also increased. The variability of the response of these markers to exercise is unknown; therefore, we examined the changes in these markers to a preloaded time trial bout of running. Nine males performed three identical trials where participants ran at 60% \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ v\dot{V}{\text{O}}_{{ 2 {\text{max}}}} $$\end{document} for 2 h interspersed with 30 s at 90% \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ v\dot{V}{\text{O}}_{{ 2 {\text{max}}}} $$\end{document} every 10 min, followed by a 5-km time trial. Blood samples were drawn at baseline, following the 2-h bout, post time trial, 1 h post time trial and the following morning. Results showed that between-subject variability (CVg) was greater than within-subject variation (CVi) for the three markers. IL-6, sIL-6R and sgp130 demonstrated a CVi of 15.3–25.5%, 15.0–17.6% and 6.2–9.4% variation, respectively, across the time points. When the data from the second and third trials were analysed independently, CVi was reduced which is supported by the time trial results for which CVi improve (4.7–2.4%). In conclusion, the results indicate that a large variation in response to exercise can be reduced following a habituation trial.
引用
收藏
页码:619 / 625
页数:6
相关论文
共 50 条
  • [21] Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases
    Susanna Nikolaus
    Georg H. Waetzig
    Sven Butzin
    Monika Ziolkiewicz
    Natalie Al-Massad
    Florian Thieme
    Ulf Lövgren
    Birgitte B. Rasmussen
    Torsten M. Reinheimer
    Dirk Seegert
    Philip Rosenstiel
    Silke Szymczak
    Stefan Schreiber
    International Journal of Colorectal Disease, 2018, 33 : 927 - 936
  • [22] CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis
    Padberg, F
    Feneberg, W
    Schmidt, S
    Schwarz, MJ
    Körschenhausen, D
    Greenberg, BD
    Nolde, T
    Müller, N
    Trapmann, H
    König, N
    Möller, HJ
    Hampel, H
    JOURNAL OF NEUROIMMUNOLOGY, 1999, 99 (02) : 218 - 223
  • [23] Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases
    Nikolaus, Susanna
    Waetzig, Georg H.
    Butzin, Sven
    Ziolkiewicz, Monika
    Al-Massad, Natalie
    Thieme, Florian
    Lovgren, Ulf
    Rasmussen, Birgitte B.
    Reinheimer, Torsten M.
    Seegert, Dirk
    Rosenstiel, Philip
    Szymczak, Silke
    Schreiber, Stefan
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2018, 33 (07) : 927 - 936
  • [24] 百草枯中毒患者的IL-6、sIL-6R、sgp130水平及其与患者预后的相关性分析
    李激文
    黎宇
    邓旺生
    钟雨
    内科, 2021, 16 (01) : 8 - 10+14
  • [25] Interleukin-6 (IL-6)/soluble interleukin-6 receptor (sIL-6R) complex, but not IL-6 or sIL-6R alone, inhibits myocardial apoptosis
    Matsushita, K
    Iwanaga, S
    Oda, T
    Kimura, K
    Shimada, M
    Tanaka, M
    Matsumura, S
    CIRCULATION, 2002, 106 (19) : 306 - 306
  • [26] Impairment of gingival fibroblast adherence by IL-6/sIL-6R
    Naruishi, K
    Takashiba, S
    Nishimura, F
    Chou, HH
    Arai, H
    Yamada, H
    Murayama, Y
    JOURNAL OF DENTAL RESEARCH, 2001, 80 (05) : 1421 - 1424
  • [27] Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma
    Giannitrapani, L
    Cervello, M
    Soresi, M
    Notarbartolo, M
    La Rosa, M
    Virruso, L
    D'Alessandro, N
    Montalto, G
    HORMONE-RELATED TUMORS: NOVEL APPROACHES TO PREVENTION AND TREATMENT, 2002, 963 : 46 - 52
  • [28] IL-6, sIL-6R/IL-6 complex and insulin-resistance in obese children
    De Filippo, Gianpaolo
    Rendina, Domenico
    Campanozzi, Angelo
    Moccia, Filomena
    Rocco, Vincenzo
    Mossetti, Giuseppe
    Melone, Maria Rita
    Spinosa, Enrico
    Mantovani, Massimo Pettoello
    HORMONE RESEARCH, 2006, 65 : 51 - 51
  • [29] CIRCULATING SOLUBLE IL-6 RECEPTOR (SIL-6R) AND IL-6/SIL-6R COMPLEX IN PATIENTS WITH SYSTEMIC-ONSET JUVENILE RHEUMATOID-ARTHRITIS (SOJRA)
    DEBENEDETTI, F
    PIGNATTI, P
    MASSA, M
    ALBANI, S
    RAMENGHI, B
    NOVICK, D
    MARTINI, A
    ARTHRITIS AND RHEUMATISM, 1993, 36 (09): : S60 - S60
  • [30] The IL-6/IL-6R/sgp130 system and Th17 associated cytokines in patients with gestational diabetes
    Kuzmicki, Mariusz
    Telejko, Beata
    Lipinska, Danuta
    Pliszka, Justyna
    Wilk, Juliusz
    Wawrusiewicz-Kurylonek, Natalia
    Zielinska, Anna
    Sobota, Angelika
    Kretowski, Adam
    Gorska, Maria
    Szamatowicz, Jacek
    ENDOKRYNOLOGIA POLSKA, 2014, 65 (03) : 169 - 175